ATE157980T1 - Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen - Google Patents

Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

Info

Publication number
ATE157980T1
ATE157980T1 AT92110270T AT92110270T ATE157980T1 AT E157980 T1 ATE157980 T1 AT E157980T1 AT 92110270 T AT92110270 T AT 92110270T AT 92110270 T AT92110270 T AT 92110270T AT E157980 T1 ATE157980 T1 AT E157980T1
Authority
AT
Austria
Prior art keywords
tetrahydropyrrolo
pyrazine
spiro
pyrrolidine derivatives
production
Prior art date
Application number
AT92110270T
Other languages
English (en)
Inventor
Toshiyuki Negoro
Makoto Murata
Shozo Ueda
Buichi Fujitani
Yoshiyuki Ono
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of ATE157980T1 publication Critical patent/ATE157980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
AT92110270T 1991-06-26 1992-06-17 Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen ATE157980T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03183185 1991-06-26

Publications (1)

Publication Number Publication Date
ATE157980T1 true ATE157980T1 (de) 1997-09-15

Family

ID=16131263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92110270T ATE157980T1 (de) 1991-06-26 1992-06-17 Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

Country Status (21)

Country Link
US (1) US5258382A (de)
EP (1) EP0520320B1 (de)
JP (1) JP2516147B2 (de)
KR (1) KR100241196B1 (de)
CN (1) CN1034176C (de)
AT (1) ATE157980T1 (de)
AU (1) AU648901B2 (de)
CA (1) CA2071273C (de)
DE (1) DE69222096T2 (de)
DK (1) DK0520320T3 (de)
ES (1) ES2108717T3 (de)
FI (1) FI98066C (de)
GR (1) GR3024870T3 (de)
HK (1) HK1001728A1 (de)
HU (1) HU218214B (de)
IE (1) IE921891A1 (de)
MX (1) MX9203231A (de)
NO (1) NO300637B1 (de)
NZ (1) NZ243255A (de)
TW (1) TW202450B (de)
ZA (1) ZA924425B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3195455B2 (ja) * 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
JP3681082B2 (ja) * 1996-06-27 2005-08-10 住友ベークライト株式会社 イミド環含有エポキシ樹脂及びエポキシ樹脂組成物
JP2007246539A (ja) * 1997-10-20 2007-09-27 Dainippon Sumitomo Pharma Co Ltd 速溶性医薬組成物
ES2224436T3 (es) * 1997-10-20 2005-03-01 Dainippon Pharmaceutical Co., Ltd. Composicion estabilizada de la tetrahidropirrolo (1,2-a) pirazino-4-espiro-3'-pirrolidina.
PT1033132E (pt) 1997-10-20 2005-09-30 Dainippon Pharmaceutical Co Composicao de farmaco rapidamente soluvel
WO2001034148A1 (fr) * 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Preparations solides pour administration orale
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
WO2004043491A1 (ja) * 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
WO2008004416A1 (fr) 2006-07-07 2008-01-10 Dainippon Sumitomo Pharma Co., Ltd. 3-amino-2,5-dioxopyrrolidine-3-carboxylate optiquement actif, procédé de production du composé, et utilisation du composé
EP2058300B1 (de) * 2006-08-31 2013-01-09 Dainippon Sumitomo Pharma Co., Ltd. Bernsteinsäurediesterderivat, verfahren zu dessen herstellung und verwendung des derivats bei der herstellung einer pharmazeutischen zubereitung
EP2071033A4 (de) 2006-09-20 2010-05-26 Nissan Chemical Ind Ltd Verfahren zur herstellung einer optisch aktiven succinimid-verbindung
EP2077261A4 (de) * 2006-09-27 2010-04-14 Nissan Chemical Ind Ltd Verfahren zur herstellung einer succinimidverbindung
WO2008038646A1 (fr) * 2006-09-29 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. PROCÉdÉ de PRODUCTION de 2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE
JP5315056B2 (ja) 2006-10-25 2013-10-16 大日本住友製薬株式会社 固結抑制粒状製剤
WO2008081860A1 (ja) * 2006-12-28 2008-07-10 Dainippon Sumitomo Pharma Co., Ltd. 光学活性コハク酸イミド誘導体およびその製造方法ならびにその使用
JPWO2008136527A1 (ja) * 2007-05-08 2010-07-29 大日本住友製薬株式会社 光学活性ジオキソピロリジン誘導体の精製方法
WO2009011410A1 (en) * 2007-07-13 2009-01-22 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain
JP2011026201A (ja) * 2007-10-17 2011-02-10 Mitsubishi Tanabe Pharma Corp 光学活性ピロリル−コハク酸イミド誘導体の立体選択的な製造方法
US8633001B2 (en) 2009-02-06 2014-01-21 Dainippon Sumitomo Pharma Co., Ltd. Process for producing optically active succinimide derivatives and intermediates thereof
WO2012014953A1 (ja) 2010-07-29 2012-02-02 大日本住友製薬株式会社 光学活性スクシンイミド誘導体の製造方法
WO2012105610A1 (ja) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
EP3192510B1 (de) * 2014-09-11 2022-01-05 Sumitomo Dainippon Pharma Co., Ltd. Ophthalmische suspensionsformulierung
CN106928234A (zh) * 2017-02-07 2017-07-07 上海合全药业股份有限公司 （2‑苄基‑1,2,3,4‑四氢吡咯并[1,2‑a]吡嗪）‑4‑甲醇的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142984A (ja) * 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4656169A (en) * 1984-08-14 1987-04-07 Pfizer Inc. Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors

Also Published As

Publication number Publication date
FI98066B (fi) 1996-12-31
AU1848392A (en) 1993-01-14
CA2071273C (en) 2002-08-20
ES2108717T3 (es) 1998-01-01
HK1001728A1 (en) 1998-07-03
DK0520320T3 (da) 1997-10-13
US5258382A (en) 1993-11-02
IE921891A1 (en) 1992-12-30
HU218214B (hu) 2000-06-28
ZA924425B (en) 1993-03-31
EP0520320B1 (de) 1997-09-10
EP0520320A2 (de) 1992-12-30
FI98066C (fi) 1997-04-10
TW202450B (de) 1993-03-21
NO922512L (no) 1992-12-28
JPH05186472A (ja) 1993-07-27
KR100241196B1 (ko) 2000-03-02
FI922848A (fi) 1992-12-27
NZ243255A (en) 1994-03-25
NO922512D0 (no) 1992-06-25
GR3024870T3 (en) 1998-01-30
EP0520320A3 (en) 1993-03-24
AU648901B2 (en) 1994-05-05
CN1034176C (zh) 1997-03-05
DE69222096T2 (de) 1998-01-22
FI922848A0 (fi) 1992-06-18
JP2516147B2 (ja) 1996-07-10
HU9202105D0 (en) 1992-10-28
CN1068825A (zh) 1993-02-10
DE69222096D1 (de) 1997-10-16
MX9203231A (es) 1993-08-01
KR930000519A (ko) 1993-01-15
HUT63424A (en) 1993-08-30
NO300637B1 (no) 1997-06-30
CA2071273A1 (en) 1992-12-27

Similar Documents

Publication Publication Date Title
ATE157980T1 (de) Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU4257889A (en) Sulphonamido-phenylalkanoic acid derivatives having thromboxane A2 antagonist activity
DE69601345D1 (de) Propiophenon-Derivate und Verfahren zur ihrer Herstellung
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
TW377352B (en) Pyrido[2,3-d]pyrimidine derivatives and pharmaceutical compositions thereof
CA2174969A1 (en) Short-acting dihydropyridines
ATE152352T1 (de) Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion
CA2042113A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
AU626740B2 (en) Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments
HUT49882A (en) Process for producing new spiro square brackets open chroman-4,4'-imidazolidine square brackets closed derivatives and pharmaceutical compositions comprising these compounds as active ingredient
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
GB8608893D0 (en) D-nor-7-ergoline derivatives
KR910020018A (ko) 피리도[3, 4-b] 피롤로[1, 2-e][1, 4, 5]옥사디아제핀 및 이의 관련 동족체 이의 제조방법 및 약제로서의 이의 용도
ATE96803T1 (de) Indolo(3,2,1-de>(1,4>-oxazino(2,3,4ij>(1,5>naphthyridinderivate, verfahren zu ihrer herstellung und zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
AU5893398A (en) Pharmaceutical composition for the treatment of so-called restless legs
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
DE69419083D1 (de) Salmycine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FI942401A (fi) 1'-amino-2-/(bentsotiatsolyyli)metyyli/spiro/isokinoliini-4(1H), 3'-pyrrolidiini/-1,2',3,5'(2H)-tetronit ja niiden analogit, jotka ovat käyttökelpoisia aldoosireduktaasin estäjinä
TH13247EX (th) อนุพันธ์เททราไฮโดรฟิร์โรโล [1,2-a]ไพราชีน-4-สไพโร-3'-พิริโรลิดีน กรรมวิธีสำหรับเตรียมสารนั้นและสารผสมในทางเภสัชกรรมซึ่งมีสารนั้น

Legal Events

Date Code Title Description
EEFA Change of the company name